Turmeric, Blood Vessels and Blood Pressure

Table of Contents

1. The Endothelium: The Organ You Have Never Heard Of
2. Flow-Mediated Dilation, Explained
3. Akazawa 2012: Curcumin and Exercise in Postmenopausal Women
4. Santos-Parker 2017: Tracing the Effect to Nitric Oxide
5. Usharani 2008: The Trial With a Statin Arm — Read Carefully
6. The Meta-Analyses on Endothelial Function
7. Blood Pressure: A Much Weaker Story
8. Nowak 2022: A Good Trial That Failed
9. Wongcharoen 2012: The One Hard Endpoint
10. What It All Adds Up To
11. Cautions
12. Key Research Papers
13. Connections
14. Featured Videos

The Endothelium: The Organ You Have Never Heard Of

Line up every blood vessel in your body end to end and you get something on the order of sixty thousand miles of tubing. The inside of all of it is coated with a single layer of flat cells called the endothelium. Laid flat, that layer would cover several tennis courts. It weighs about as much as your liver. It is, by any reasonable definition, an organ — and almost nobody has heard of it.

It is not passive plumbing lining. The endothelium continuously senses the blood rushing past it and responds: releasing nitric oxide to relax the vessel and lower resistance, releasing other signals to tighten it, controlling whether platelets stick, whether white blood cells cross into the vessel wall, whether the wall becomes inflamed. Practically every step of atherosclerosis begins with the endothelium failing at one of those jobs.

Endothelial dysfunction is the earliest measurable stage of cardiovascular disease. It appears years, sometimes decades, before a narrowed artery shows up on a scan. Diabetes, smoking, high blood pressure, high LDL and simple ageing all damage it, largely through oxidative stress: reactive oxygen molecules chemically consume nitric oxide faster than the endothelium can produce it, so the vessel loses its ability to relax on demand.

That is why researchers measure endothelial function when testing an antioxidant or anti-inflammatory compound. It is the earliest point in the disease process where an intervention could plausibly show an effect, and it can be measured non-invasively in an afternoon. It is still a surrogate — nobody has an endothelial-dysfunction heart attack — but it is a well-reasoned one.

Back to Table of Contents

Flow-Mediated Dilation, Explained

Flow-mediated dilation, abbreviated FMD, is the standard way of measuring endothelial function in a living person, and it is a genuinely clever test.

Here is how it works. An ultrasound probe is placed over the brachial artery in your upper arm and the artery's diameter is measured precisely. A blood-pressure cuff on the forearm is then inflated hard enough to stop blood flow completely, and held there for five minutes. Downstream, starved of oxygen, the small vessels dilate wide open. Then the cuff is released and blood surges through the brachial artery at far above its normal rate.

The analogy: imagine kinking a garden hose for five minutes and then letting go. The rush of water that follows drags hard along the inside of the hose. A living artery, unlike a hose, feels that drag. The endothelial cells sense the shear stress of the accelerating blood and respond by releasing nitric oxide, which relaxes the muscle in the vessel wall and lets the artery widen to accommodate the flow. The ultrasound measures how much wider it got.

FMD is reported as a percentage increase in diameter over baseline. Healthy young arteries manage a substantial widening; damaged ones barely move. A typical trial reports a change of one or two percentage points, which sounds trivial until you realise the whole scale runs from roughly two to ten percent. Lower FMD predicts future cardiovascular events in population studies, independently of the usual risk factors.

Two honest caveats. First, FMD is technically demanding — the measurement is of fractions of a millimetre, and it is sensitive to the operator, the time of day, the room temperature, caffeine, and what the participant ate. Results from different laboratories are not always comparable. Second, and more fundamentally, improving FMD is not the same as preventing a heart attack. It is the earliest plausible signal, not the destination.

The other measure that appears on this page is pulse wave velocity, which assesses something different: arterial stiffness. Each heartbeat sends a pressure wave down the aorta, and the speed of that wave depends on how rigid the vessel is — the stiffer the pipe, the faster the wave. It is a structural property rather than a moment-to-moment chemical response, and it tends to be harder to change. Notably, curcumin trials have moved FMD more readily than they have moved arterial stiffness.

Back to Table of Contents

Akazawa 2012: Curcumin and Exercise in Postmenopausal Women

A 2012 trial in Nutrition Research asked a well-framed question in a population where it matters. Oestrogen supports endothelial function, and after menopause its withdrawal is followed by a measurable decline in how well arteries dilate — part of why cardiovascular risk in women rises steeply after menopause.

The study enrolled 32 postmenopausal women and divided them across three arms over eight weeks: a control group, a group doing regular aerobic exercise training, and a group taking curcumin at a modest daily dose. Brachial artery FMD was measured before and after.

Both the exercise group and the curcumin group improved their FMD significantly compared with control, and by broadly comparable amounts. The obvious and correct interpretation is that curcumin improved endothelial function in this population. The equally important second reading is that the comparison arm was exercise — a free, non-toxic intervention with an enormous body of hard outcome evidence behind it, benefits that extend to bone, mood, muscle, sleep and mortality, and no risk of liver injury.

The limitations are the ones that recur throughout this leg. Thirty-two people across three arms leaves roughly ten per group, which is very small. Eight weeks is short. It is a single centre. And the dose was modest by the standards of later trials, using an ordinary curcumin preparation rather than an absorption-enhanced one, which makes the positive result slightly puzzling in light of how little plain curcumin reaches the blood.

Back to Table of Contents

Santos-Parker 2017: Tracing the Effect to Nitric Oxide

The 2017 trial published in Aging is, methodologically, the most interesting endothelial study in the turmeric literature — not because of its size, but because of what it did after finding an effect.

Healthy middle-aged and older adults were randomised to a bioavailability-enhanced curcumin formulation or placebo for twelve weeks. Brachial artery FMD improved substantially in the curcumin group — an increase of roughly a third over baseline, which in a population whose vessels had been stiffening for decades is a meaningful amount of recovered function.

What distinguishes the study is the follow-up experiment. Rather than stopping at "FMD improved," the investigators went looking for the mechanism, and demonstrated that the improvement was attributable to greater nitric oxide bioavailability — with a contribution from reduced oxidative stress in the vessel wall. That is the precise pathway the laboratory work predicts. When a human trial confirms not only the effect but the specific molecular route to it, the finding is considerably harder to explain away as chance or as a placebo response.

Two things temper the enthusiasm. The trial was small and single-centre, like everything else here. And its improvement in FMD was not matched by a comparable improvement in large-artery stiffness — the endothelium got better at responding; the pipe itself did not become more elastic. That dissociation is worth holding on to, because it recurs in the negative trial described below.

Back to Table of Contents

Usharani 2008: The Trial With a Statin Arm — Read Carefully

This is the study most often misrepresented on the internet, so it needs describing precisely.

In 2008, a trial published in Drugs in R&D randomised people with type 2 diabetes to one of three arms: a standardised curcumin preparation, atorvastatin, or placebo, over eight weeks. The measurements were endothelial function, markers of oxidative stress including malondialdehyde, and inflammatory markers including endothelin-1, interleukin-6 and TNF-alpha.

Both active arms improved those measurements relative to placebo, by broadly similar amounts. That is an interesting result and worth knowing.

Here is what it does not show. It does not show that curcumin works as well as a statin. It cannot, because it never measured what statins are prescribed to achieve. Statins are given to prevent heart attacks, strokes and cardiovascular death, and that benefit was established in outcome trials involving hundreds of thousands of participants followed for years. This trial followed a modest number of people for eight weeks and measured blood chemistry and ultrasound. Moving an inflammatory marker the same distance as a statin does over two months tells you nothing about whether the same events would be prevented over ten.

The trap here is called surrogate equivalence, and it has misled better-resourced people than internet readers. Two interventions that move the same marker identically can have completely different effects on patients — because they reach the marker by different routes, with different effects on everything the marker does not measure. The history of cardiology contains drugs that improved their markers beautifully and increased deaths.

Read Usharani 2008 as what it is: a small, short, mechanistically interesting trial showing that a curcumin preparation moves vascular markers in a favourable direction in people with type 2 diabetes. Anyone who quotes it as evidence of statin equivalence is either misunderstanding it or hoping you will.

Back to Table of Contents

The Meta-Analyses on Endothelial Function

Two pooled analyses are worth knowing here, and they sit at different levels of abstraction.

A 2020 meta-analysis in Complementary Medicine Research gathered the randomised trials measuring flow-mediated dilation and endothelial function after curcumin preparations, and concluded that they can improve both. Pooling is more defensible for FMD than for lipids, because FMD is measured in a reasonably standardised way across laboratories and expressed on a common scale — though the technical sensitivity of the measurement still introduces variation between centres.

A 2024 analysis in Prostaglandins and Other Lipid Mediators went a level higher: a meta-analysis of meta-analyses, examining the effect of curcumin on endothelial function and blood pressure in people with metabolic disorders. An umbrella review of this kind is useful for seeing whether independent pooled analyses converge, and for catching the case where several of them are quietly recycling the same underlying trials.

That last point is the one to keep in view. An umbrella review looks like the strongest possible evidence — a summary of summaries — but it inherits every weakness of the primary studies at the bottom of the stack, and adds a new one: the meta-analyses it pools are not independent of each other when they share most of their input trials. Layers of synthesis do not manufacture evidence. Underneath all of it sit the same few dozen small, short, single-centre studies.

Back to Table of Contents

Blood Pressure: A Much Weaker Story

Given the nitric oxide mechanism, you would expect a blood-pressure effect: nitric oxide relaxes vessels, relaxed vessels offer less resistance, less resistance means lower pressure. The evidence is thinner than that reasoning suggests.

A 2026 systematic review and meta-analysis in Endocrinology, Diabetes and Metabolism examined the antihypertensive effects of curcumin and turmeric supplementation specifically in prediabetes and diabetes. Restricting the population is sensible: any blood-pressure effect should be easiest to detect in people whose vascular biology is already impaired.

Across this literature, reported blood-pressure reductions are small — the order of a few millimetres of mercury in pooled analyses, when they reach significance at all, and inconsistent between studies. For comparison, a standard antihypertensive drug typically lowers systolic pressure by ten millimetres or more, losing weight lowers it substantially, and reducing salt intake or taking up regular exercise each produce changes in the same range as an entire class of supplement effects.

Blood pressure is also a difficult thing to measure well. It varies minute to minute, rises in clinical settings, and differs between a single office reading and twenty-four-hour ambulatory monitoring. Small trials using office readings can produce apparent changes that are measurement noise. Meta-analyses of such trials inherit the noise and present it with a tidy confidence interval.

The honest summary: turmeric is not a treatment for hypertension. If your blood pressure is high, the interventions with real evidence are weight, salt, alcohol, exercise, sleep and, where indicated, medication.

Back to Table of Contents

Nowak 2022: A Good Trial That Failed

This section exists because a health page that reports only positive findings is not reporting.

In 2022 the Clinical Journal of the American Society of Nephrology published a randomised controlled trial of curcumin therapy in children and young adults with autosomal dominant polycystic kidney disease. ADPKD is an inherited condition in which fluid-filled cysts gradually replace functioning kidney tissue, and it comes with early vascular dysfunction — young patients have impaired endothelial function and stiffer arteries long before their kidney function declines. The rationale for testing an antioxidant and anti-inflammatory compound in them was excellent.

The trial was well designed by the standards of this field: 68 participants aged from childhood into their twenties, twelve months of treatment, a substantial weight-based curcumin dose, placebo control, and pre-specified primary endpoints — vascular endothelial function, aortic stiffness, and the rate of kidney growth measured by imaging.

It did not meet its primary endpoints. Curcumin did not produce a significant improvement in vascular function in this population, nor did it slow the growth of the kidneys. (A correction to the published article was later issued; the trial's findings stand.)

Why does a null result in a rare kidney disease matter for a page about turmeric and blood vessels? Because it is one of the longest and best-designed vascular trials in the entire curcumin literature, and it came out negative. That has to count. Several things could explain it — a young population whose vessels may not be damaged in the way an older population's are, a disease process driven by mechanisms curcumin does not touch, or simply that the earlier positive FMD results were smaller than they appeared. But the explanation that cannot be used is silence.

There is a broader lesson here about how supplement evidence accumulates. Small positive trials get publicised, repeated in marketing copy and folded into meta-analyses. Larger, longer, better-designed null trials get published quietly and cited rarely. If you only ever encounter the positive half of a literature, you will systematically overestimate what an intervention does. Nowak 2022 is the half you were less likely to be shown.

Back to Table of Contents

Wongcharoen 2012: The One Hard Endpoint

And now the study that is different in kind from everything above.

Coronary artery bypass grafting is major surgery: the chest is opened, blood is routed through a heart-lung machine, and grafts are sewn in to carry blood around blocked coronary arteries. One of its recognised complications is a heart attack occurring during or shortly after the operation. The mechanism is partly ischaemia-reperfusion injury — heart muscle deprived of blood, then flooded with it again, suffers a burst of oxidative stress and inflammation as the oxygen returns. That is precisely the kind of injury an antioxidant and anti-inflammatory compound might plausibly blunt, and it happens over days rather than decades, which makes it measurable in a small trial.

The team at Chiang Mai University tested exactly that. In a trial published in the American Journal of Cardiology in 2012, 121 patients scheduled for bypass surgery were randomised to high-dose curcuminoids or placebo, beginning three days before the operation and continuing for five days afterwards.

The endpoint was the occurrence of in-hospital myocardial infarction, diagnosed by standard post-operative criteria. About 13 percent of the curcuminoid group had one, against roughly 30 percent of the placebo group. Markers of inflammation and oxidative stress fell in parallel in the treated group, which makes the result mechanistically coherent rather than an isolated statistical event.

Why this matters. It is the only study on this entire leg where the thing being counted is something that happened to a patient. Everything else is a number on a report. If you were to keep one study from this collection, it would be this one.

Why it is not settled. One hospital, one country, one surgical team, 121 patients. The difference between the arms rests on a small number of events, and in a trial this size a handful of cases either way swings the percentage substantially. Perioperative trials of this scale have a poor record of reproducing. And after fourteen years, no independent group has repeated it — despite the trial being cheap, ethically straightforward and entirely feasible to run at multiple centres. That absence does not refute the finding, but it does mean the surgical world has not been persuaded to act on it.

The right posture is genuine interest without conviction. Wongcharoen 2012 is the best argument in existence for funding a large multi-centre trial of perioperative curcuminoids. It is not evidence that turmeric prevents heart attacks in ordinary life, a setting it never studied.

Back to Table of Contents

What It All Adds Up To

Laying the whole page out honestly:

• The mechanism is real and specific. Curcumin increases nitric oxide availability and reduces vascular oxidative stress, and the Santos-Parker trial demonstrated that route in humans rather than only in cell culture.
• Several small trials show improved flow-mediated dilation. Consistently enough that a pooled analysis finds it.
• The best long trial in the field was negative. Twelve months, pre-specified endpoints, a serious population — and no significant vascular benefit.
• Blood pressure effects are small at best. This is not a treatment for hypertension.
• Arterial stiffness moves less readily than endothelial function. The lining responds; the structure of the pipe largely does not.
• One trial counted actual heart attacks, and the result was encouraging. Single-centre, unreplicated, in a surgical setting unlike daily life.
• No trial has ever tested whether turmeric prevents cardiovascular events in ordinary people. Not one. Everything else is inference across a gap nobody has crossed.

If you are working on your cardiovascular health, the interventions with hard outcome evidence are exercise, not smoking, sleep, weight, blood-pressure control and — where your risk warrants it — lipid-lowering medication. Turmeric is a plausible, low-risk addition to that. It is not one of the pillars, and it does not replace any of them.

Back to Table of Contents

Cautions

• Antiplatelet effect and surgery. Curcumin inhibits platelet aggregation in the laboratory. Note the irony of the bypass trial: its participants were given curcuminoids under close hospital supervision with surgical bleeding monitored. That is not the same as taking a supplement unsupervised before an operation. Stop one to two weeks before any planned procedure and tell the team.
• Anticoagulants and antiplatelet drugs. Warfarin, direct oral anticoagulants, clopidogrel and daily aspirin all warrant a conversation with a prescriber before adding a concentrated turmeric product.
• Blood pressure medication. Any additional vasodilating effect stacks with what you are already taking. If you are on antihypertensives, monitor when starting.
• Liver injury. Uncommon but documented and sometimes severe; a 2023 case series from the Drug-Induced Liver Injury Network described ten cases, with absorption-enhanced products over-represented. Stop for jaundice, dark urine, pale stools or persistent right-upper-abdominal pain.
• Piperine interactions. The absorption enhancer raises blood levels of other drugs cleared by the same enzymes.
• Gallbladder disease. Avoid concentrated doses with known gallstones or biliary obstruction.

The complete treatment is on the Turmeric Safety and Interactions leg.

Back to Table of Contents

Key Research Papers

1. Wongcharoen W, Jai-Aue S, Phrommintikul A, et al. (2012). Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. American Journal of Cardiology. (The only hard-endpoint trial in this leg; single-centre and unreplicated.) — PubMed PMID: 22481014
2. Santos-Parker JR, Strahler TR, Bassett CJ, et al. (2017). Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability. Aging (Albany NY). — PubMed PMID: 28070018
3. Akazawa N, Choi Y, Miyaki A, et al. (2012). Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutrition Research. — PubMed PMID: 23146777
4. Nowak KL, Farmer-Bailey H, Wang W, et al. (2022). Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology. (A twelve-month trial that did not meet its primary endpoints.) — PubMed PMID: 34907021
5. Usharani P, Mateen AA, Naidu MU, et al. (2008). Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs in R&D. (Surrogate markers over eight weeks; not a comparison of clinical outcomes.) — PubMed PMID: 18588355
6. Changal KH, Khan MS, Bashir R, et al. (2020). Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis. Complementary Medicine Research. — PubMed PMID: 32101871
7. Tang WW, Huang FF, Haedi AR, et al. (2024). The effect of curcumin supplementation on endothelial function and blood pressure in patients with metabolic disorders: A meta-analysis of meta-analyses. Prostaglandins and Other Lipid Mediators. — PubMed PMID: 39265778
8. Bahari H, Sharifi M, Nejad Shahrokh Abadi Z, et al. (2026). Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes and Metabolism. — PubMed PMID: 41388744
9. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, et al. (2014). Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. Journal of Nutritional Biochemistry. — PubMed PMID: 24445038
10. Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. — PubMed PMID: 9619120
11. Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. Journal of Medicinal Chemistry. — PubMed PMID: 28074653
12. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. American Journal of Medicine. — PubMed PMID: 36252717

PubMed Topic Searches

1. PubMed: Curcumin and flow-mediated dilation
2. PubMed: Curcumin and endothelial function, randomized trials
3. PubMed: Curcumin and nitric oxide bioavailability
4. PubMed: Curcumin and blood pressure
5. PubMed: Curcumin, arterial stiffness and pulse wave velocity
6. PubMed: Curcuminoids in cardiac surgery and reperfusion injury
7. PubMed: Endothelial dysfunction and cardiovascular risk prediction
8. PubMed: Reproducibility of flow-mediated dilation measurement

Back to Table of Contents

Connections

• Turmeric for Heart and Metabolic Health
• Turmeric for Blood Sugar and Type 2 Diabetes
• Turmeric and Cholesterol
• Turmeric for Fatty Liver and Metabolic Syndrome
• Turmeric
• Turmeric, Inflammation and Joint Health
• Turmeric Bioavailability and Forms
• Turmeric Safety and Interactions
• Turmeric for Digestive Health
• History of Turmeric
• Javanese Turmeric
• Black Ginger
• Culinary and Spice Herbs
• All Herbs

Back to Table of Contents